Editorial Material
Cell & Tissue Engineering
Malini Gupta, Britta Will
Summary: Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this study, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as a targeted opportunity for mitigating malignant cell growth in AML.
Article
Medicine, Legal
Elena M. Fenu, Stacey S. O'Neill, Giovanni Insuasti-Beltran, Mark J. Pettenati, Mark Giffen, William T. Harrison
Summary: Acute myeloid leukemia can rarely lead to sudden death in children, even those without prior medical history. This case emphasizes the importance of considering acute leukemia in the differential diagnosis during autopsies, and the resources available for postmortem workup of acute leukemias.
AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY
(2021)
Article
Medicine, Legal
Lila Krebs-Drouot, Georgia Karpathiou, Virginie Scolan, Carolyne Bidat-Callet, Baptiste Boyer, Michel Peoc'h
Summary: This report analyzes the rare phenomenon of acute myeloid leukemia (AML) diagnosed at autopsy after sudden death. Three cases of young women diagnosed with AML only after autopsy are reported, along with a literature review. Although the diagnosis of AML during autopsy is rare, it can raise forensic issues and requires a complete autopsy with pathology analysis.
FORENSIC SCIENCE MEDICINE AND PATHOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Daniela Damiani, Mario Tiribelli
Summary: The prognosis of acute myeloid leukemia (AML) is poor due to tumor cell immune escape, which weakens T-cells. Inhibiting immune checkpoints (ICs) through immune checkpoint inhibitors (ICIs) has emerged as a promising therapeutic strategy for AML. However, the results of clinical trials testing ICIs, alone or in combination with other treatments, in AML are conflicting.
Review
Biochemistry & Molecular Biology
Vijendra Singh, Mohammed Hafiz Uddin, Jeffrey A. Zonder, Asfar S. Azmi, Suresh Kumar Balasubramanian
Summary: While mechanistic studies have shed light on the molecular mechanisms of AML and led to the development of new targeted therapies, resistance remains a significant issue in AML treatment. The exploration of circRNA in AML biology and therapy resistance shows promise in providing new insights and potential solutions to managing this disease.
Review
Biochemistry & Molecular Biology
Rikako Tabata, SungGi Chi, Junichiro Yuda, Yosuke Minami
Summary: Studies have suggested the potential clinical benefits of immuno-oncology therapy against AML, including immune checkpoint inhibitors and bi-/tri-specific antibodies. CAR-T and NK cells have shown effectiveness for relapsed/refractory AML patients, and conventional chemotherapy combined with anti-PD-1/anti-CTLA4 antibodies also demonstrated certain efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Hematology
Matthew Tcheng, Alessia Roma, Nawaz Ahmed, Richard W. Smith, Preethi Jayanth, Mark D. Minden, Aaron D. Schimmer, David A. Hess, Kristin Hope, Kevin A. Rea, Tariq A. Akhtar, Eric Bohmsen, Angelo D'Alessandro, Al-Walid Mohsen, Jerry Vockley, Paul A. Spagnuolo
Summary: By studying the metabolic characteristics of AML cells, it was found that the FAO enzyme VLCAD plays a crucial role in mitochondrial metabolism and cell survival. Inhibiting VLCAD leads to AML cell death while having no impact on normal hematopoietic cells.
Article
Biology
Xiyue Yan, Juan Liu, Yu Ben, Weicheng Zheng, Pan Hu, Yaping Zhang, Wenyu Shi
Summary: Follicular lymphoma (FL) is a prevalent indolent lymphoma with a risk of histological transformation. In rare cases, the transformation can occur to other cell lineages, such as acute myeloid leukemia (AML). The low incidence and poor prognosis of B-myeloid transformation hinder the understanding of its molecular mechanisms.
Article
Oncology
Yazhen Bi, Saran Feng, Jinyu Shang, Qian Liu, Yan Wang
Summary: The occurrence of primary pulmonary lymphoma (PPL) as a secondary malignancy in patients diagnosed with chronic myeloid leukemia (CML) is extremely rare. Most patients with PPL tend to be misdiagnosed with pneumonia due to atypical clinical manifestations. In cases where the patient's recurrent respiratory symptoms and imaging findings do not coincide, secondary tumors should be considered in addition to infection as a diagnosis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Fenghua Qian, Brooke E. Arner, Kathleen M. Kelly, Charyguly Annageldiyev, Arati Sharma, David F. Claxton, Robert F. Paulson, K. Sandeep Prabhu
Summary: Interleukin-4 (IL-4) plays a therapeutic role in acute myeloid leukemia (AML) by alleviating the severity of the disease. IL-4 enhances the expression of hematopoietic- PGD(2) synthase (H-PGDS) to increase the production of endogenous cyclopentenone prostaglandins (CyPGs), leading to apoptosis of leukemia-initiating cells (LICs).
Article
Medicine, Legal
Oluwaseun B. Ogunbona, Michael Heninger, Kyle Bradley, Rachel Geller
Summary: This report describes a case of sudden death caused by undiagnosed classic Hodgkin lymphoma in an 18-year-old female. The autopsy revealed a bulky mass compressing important organs, collapsed lungs, and a rare instance of natural sudden death due to undiagnosed lymphoma.
JOURNAL OF FORENSIC SCIENCES
(2022)
Article
Critical Care Medicine
Carolina Secreto, Dara Chean, Andry van de Louw, Achille Kouatchet, Philippe Bauer, Marco Cerrano, Etienne Lengline, Colombe Saillard, Laurent Chow-Chine, Anders Perner, Peter Pickkers, Marcio Soares, Jordi Rello, Frederic Pene, Virginie Lemiale, Michael Darmon, Sofiane Fodil, Ignacio Martin-Loeches, Sangeeta Mehta, Peter Schellongowski, Elie Azoulay, Djamel Mokart
Summary: Acute respiratory failure (ARF) in patients with Acute Myeloid Leukemia (AML) is a common reason for ICU admission. This study aimed to assess the hospital mortality and risk factors associated with AML and ARF, and define specific subgroups through cluster analysis. The results showed a hospital mortality rate of 46.8%. Factors independently associated with mortality include performance status, cough, use of vasopressors, leukemia-specific pulmonary involvement, and liver SOFA score. Three distinct ARF syndromes were identified: leukemic cluster, pulmonary cluster, and clinical inflammatory cluster, which were also associated with hospital mortality.
ANNALS OF INTENSIVE CARE
(2023)
Review
Oncology
Kristen J. Kurtz, Shannon E. Conneely, Madeleine O'Keefe, Katharina Wohlan, Rachel E. Rau
Summary: Acute myeloid leukemia (AML) is a genetically and phenotypically heterogeneous hematologic malignancy. Murine models of AML are indispensable research tools to better understand the mechanisms and test novel therapeutic approaches for this disease.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, Research & Experimental
Mengci Hu, Wenzhe Li, Youshan Zhang, Caixia Liang, Jie Tan, Ya Wang
Summary: Venetoclax, a potent BCL-2 inhibitor, has shown significant efficacy in AML treatment in preclinical and clinical trials. However, further research is needed to determine the optimal treatment strategies and identify biomarkers for predicting treatment response.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Biotechnology & Applied Microbiology
Edyta Paczkowska, Michal Janowski, Katarzyna Karpinska, Malorzata Rylow, Barbara Zdziarska, Wojciech Poncyljusz, Boguslaw Machalinski
Summary: This report describes a case of secondary Hodgkin lymphoma in a patient with chronic myeloid leukaemia who was treated with dasatinib as a third-line therapy. The patient achieved complete metabolic remission of Hodgkin lymphoma with AVD chemotherapy while maintaining a deep molecular response to dasatinib at a reduced dose. The combination of dasatinib and AVD regimens showed efficacy and safety in treating coexisting CML and HL.
ONCOTARGETS AND THERAPY
(2021)